Arrhythmia
Read Time: < 1 min

16/Effects of sodium-glucose cotransporter-2 inhibitors on ventricular arrhythmias or sudden cardiac death: a propensity score-matched population-based study

Published Online: October 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr16
Authors: K Bin Waleed (Presenting Author) – St George’s University Hospital NHS Foundation Trust, London; MM Gallagher – St George’s University Hospital NHS Foundation Trust, London; S Lee – Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong; J Zhou – Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong; T Liu – 2nd Hospital of Tianjin Medical University, Tianjin; X Liu – Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong; TTL Lee – Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong; WT Wong – Chinese University of Hong Kong, Shenzhen Research Institute, Hong Kong; BMY Cheung – The University of Hong Kong, Hong Kong; Q Zhang – City University of Hong Kong, Hong Kong; G Tse – 2nd Hospital of Tianjin Medical University, Tianjin
Quick Links:
Article
Article Information
Article:

Introduction: Numerous trials have studied the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2Is) on ventricular tachycardia/fibrillation (VT/VF) or sudden cardiac death (SCD), with conflicting findings. However, this has not been explored in population-based real-world studies. We compared the risks of VT/VF/SCD between SGLT2I and dipeptidyl peptidase-4 inhibitors (DPP4Is) in a Chinese population.

Methods: The was a retrospective cohort study of SGLT2I/DPP4I users between 1 January 2015 and 31 December 2019 in public hospitals, outpatient/ambulatory care facilities in Hong Kong. The primary outcome was VT/VF/SCD with follow-up until 31 December 2019. Propensity score matching with nearest neighbour search (1:1), inverse probability treatment weighting (IPTW), propensity score stratification and high-dimensional propensity score (HDPS) adjustments were used.

Results: A total of 69,128 patients (median age: 65.5 years [standard deviation (SD): 12.9], 55.5% males; 28,678 SGLT2I vs 40,450 DPP4I users) were included. After matching for demographics, comorbidities, anti-diabetic and cardiovascular drugs, fasting glucose and HbA1c, 100 patients (incidence rate [IR]: 0.46%) developed VT/VF/SCD, with significant difference between SGLT2I (21/10,766; IR: 0.19%) and DPP4I (79/10,766, IR: 0.73%) users (p<0.001). Cox regression showed that SGLT2I use was associated with lower risks of VT/VF/SCD compared with DPP4I use (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.26–0.70; p<0.0007). IPTW (HR 0.42, 95% CI 0.33–0.71; p<0.0001), propensity score stratification (HR 0.46, 95% CI 0.31–0.65; p<0.0001) and HDPS adjustment (HR 0.43, 95% CI 0.30–0.69; p<0.0001) produced similar results.

Conclusions and implications: SGLT2I use was significantly associated with lower risks of VT/VF/SCD compared with DPP4I use amongst patients with type 2 diabetes mellitus. 

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72